Amakem, a Belgian kinase platform company focused on ophthalmic treatments, has appointed Maarten van Geffen, an industry veteran of 25 years, as head of Chemistry, Manufacturing and Controls (CMC) and operations.
Van Geffen was previously director of product development at Shire-Movetis, where he was responsible for the pharmaceutical development of GI early and late phase products and was CMC lead for due diligence of early phase and late phase small and large molecule products. He also played a pivotal role in the strategic development of commercial and pipeline products as well as carrying out quality control on dossiers and interacting with regulatory authorities.
Prior to this, van Geffen held several positions as director of CMC Regulatory Affairs at Barrier Therapeutic, Centocor, and Janssen Research Foundation.
Amakem’s leading drug candidate, AMA0076, is for glaucoma.
